Overview

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Pomalidomide is a newly discovered drug that may stop cancer cells from growing abnormally. Pomalidomide may also stimulate the immune system to fight the cancer cells and possibly improve the effectiveness of dexamethasone and rituximab to fight the Waldenstrom's Macroglobulinemia (WM) cancer cells. This drug have been used in multiple myeloma and information from these other research studies suggests that Pomalidomide may help to reduce or prevent the growth of cancer cells.
Phase:
Phase 1
Details
Lead Sponsor:
Steven P. Treon, MD, PhD
Collaborator:
Celgene Corporation
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Pomalidomide
Rituximab
Thalidomide